Placental malaria (PM) is characterized by infected erythrocytes (IEs) that selectively bind to
chondroitin sulfate A (CSA) and sequester in placental tissue. Variant surface antigen 2-CSA …

Background: Vaccine antigens targeting specific P. falciparum parasite stages are under pre-
clinical and clinical development. It seems plausible that vaccine with multiple specificities …

Background Malaria in pregnancy is associated with significant morbidity in pregnant
women and their offspring. Plasmodium falciparum infected erythrocytes (IE) express …

Background In Plasmodium falciparum malaria endemic areas placental malaria (PM) is an
important complication of malaria. The recurrence of malaria in primigravidae women …

Interactions between parasite-encoded proteins and host carbohydrate molecules are
essential at multiple stages in the life cycle of the malaria-causing parasite, Plasmodium …

In high malaria transmission settings, the use of sulfadoxine-pyrimethamine-based
intermittent preventive treatment during pregnancy (IPTp-SP) has resulted in decreased …

Plasmodium falciparum infection during pregnancy results in the sequestration of infected
red blood cells (IRBCs) in the placenta, contributing to pregnancy associated malaria (PAM) …

Background. Malaria during pregnancy may threaten the mother's health and cause serious
structural damage to the internal architecture of the placenta, which subsequently affects the …

Pregnant women infected with Plasmodium falciparum often produce antibodies (Abs) to
VAR2CSA, a ligand that binds to placental chondroitin sulfate A causing placental malaria …

The Plasmodium falciparum protein VAR2CSA is a critical mediator of placental malaria,
and VAR2CSA antibodies (IgGs) are important to protect pregnant women. Although …